The Cellular Response to Oxidatively Induced DNA Damage and Polymorphism of Some DNA Repair Genes Associated with Clinicopathological Features of Bladder Cancer
Table 7
Distribution of genotypes of some DNA repair genes in non-muscle-invasive (Ta/T1) and muscle-invasive () tumors depending on their differentiation.
DNA repair gene polymorphisms
Genotype frequency (%) depending on the tumor stages and grades
Ta/T1
G1
G2
G3
low
high
OGG1 326 rs1052133
Ser/Ser
67.0
69.0
71.1
65.9
67.4
67.5
69.2
Ser/Cys
28.8
27.0
24.4
30.8
27.9
28.8
26.3
Cys/Cys
4.2
4.0
4.4
3.2
4.7
3.8
4.5
XRCC1 399 rs25487
Arg/Arg
39.6
44.4
41.5
38.2
46.5
39.0
44.2
Arg/Gln
49.0
44.4
48.9
48.4
43.0
48.5
44.9
Gln/Gln
11.5
11.1
9.6
13.4
10.5
12.5
10.9
XPD 312 rs1799793
Asp/Asp
29.2
32.5
24.4
35.7
30.2
31.3
30.8
Asp/Asn
54.5
49.2
62.2
44.9
52.3
53.7
49.3
Asn/Asn
16.3
18.3
13.3
19.5
17.5
15.0
19.9
XPD 751 rs13181
Lys/Lys
28.9
30.6
28.2
30.4
31.0
31.2
28.3
Lys/Gln
53.2
51.6
57.3
49.2
51.2
52.1
52.0
Gln/Gln
17.9
17.7
14.5
20.4
17.8
16.7
19.7
ERCC6 1097 rs2228526
Met/Met
50.9
46.8
57.0
45.2
47.7
48.1
49.3
Met/Val
44.3
40.5
37.8
47.3
43.0
45.6
41.7
Val/Val
4.8
12.7a
5.2
7.5
9.3
6.2
9.0
ERCC6 399 rs2228528
Gly/Gly
67.8
67.5
65.4
69.4
67.0
65.7
69.7
Gly/Asp
29.0
30.2
31.6
27.3
30.6
31.4
27.7
Asp/Asp
3.2
2.4
3.0
3.3
2.4
2.9
2.6
Significant differences were observed between Ta/T1 and tumors with respect to frequencies of the homozygous ERCC6 1097 Val/Val genotype according to test ( = 0.0045).
